Every cardio-thoracic anesthesiologist knows the tension. Cardiac and thoracic surgery are among the most physiologically demanding operations, and the patients are often fragile. A sternotomy or thoracotomy is also intensely painful. For decades, opioids were the answer, and their costs came with them: respiratory depression, nausea, ileus, delirium, and delayed extubation. As Austin Harris MD, a cardio-thoracic anesthesiologist, I’ve spent much of my career looking for ways to ease pain without destabilizing a heart or compromising a lung. Perioperative ketamine, delivered as a carefully managed infusion, has become one of the most useful tools I have.
Why Ketamine Deserves a Second Look
Many clinicians still think of ketamine as a dissociative induction agent or an emergency-room sedative. That picture is incomplete. At the low, sub-anesthetic doses used for ketamine infusion therapy, the drug works differently. It acts mainly as an NMDA receptor antagonist. This is a pathway involved in central sensitization, the process by which the nervous system amplifies pain signals after tissue injury. Blocking it can reduce acute pain and may blunt opioid tolerance and opioid-induced hyperalgesia, in which opioids paradoxically heighten pain sensitivity.
That mechanism fits cardio-thoracic surgery well. Rib spreading, sternal retraction, and pleural irritation produce a sustained nociceptive barrage, the kind of stimulus that fuels central sensitization. In my practice, I think of low-dose ketamine as a way to quiet that signaling at the source rather than simply covering it with more opioid.
A Pharmacologic Profile That Suits the Heart and Lungs
Unlike most anesthetic agents, ketamine tends to support rather than depress the circulation. Through sympathetic stimulation, it generally maintains heart rate, blood pressure, and cardiac output. For a patient with limited reserve, that hemodynamic stability in cardiac surgery is valuable. It is one reason ketamine has long been used in induction for critically ill and hemodynamically fragile patients.
It also helps on the thoracic side. Ketamine has bronchodilating properties and tends to preserve airway reflexes and respiratory drive, which matters for patients with reactive airway disease or limited pulmonary reserve. When thoracic surgery anesthesia has to protect a patient with marginal lung function, an opioid-sparing strategy can mean the difference between a smooth recovery and a prolonged ventilator course.
Benefits I See in Cardiac and Thoracic Patients
The most consistent benefit is opioid-sparing anesthesia. Evidence from perioperative studies, including consensus guidelines on intravenous ketamine for acute pain from major pain-society groups, supports its use as an adjunct that can reduce postoperative opioid consumption and pain scores, particularly in patients undergoing painful procedures or with existing opioid exposure. Using less opioid means less sedation, less nausea, and a better chance of early mobilization.
For ketamine for postoperative pain after thoracotomy and sternotomy, a multimodal approach works best. Regional techniques such as paravertebral or erector spinae plane blocks, acetaminophen, and judicious use of other adjuncts all play a part. Ketamine fits alongside them. It is one layer of analgesia, not a replacement for the others.
There are also less certain but intriguing possibilities. Ketamine has shown anti-inflammatory effects in laboratory and some clinical settings, which is relevant to the systemic inflammatory response triggered by cardiopulmonary bypass. Neuroprotective potential is another area of interest, given the risk of postoperative cognitive dysfunction and delirium in older cardiac patients. I want to be clear about the state of the evidence here. Large trials of ketamine for preventing postoperative delirium, including a prominent randomized trial in major surgery, did not show a reduction in delirium and did show more hallucinations and nightmares at higher doses. These are promising hypotheses, not established benefits, and I try to describe them honestly to colleagues and patients.
Finally, there is the question of chronic post-surgical pain. Persistent pain after thoracic surgery affects a meaningful proportion of patients, and reducing central sensitization early is an attractive strategy. The data on long-term outcomes are mixed, but the rationale is sound and worth continued study.
Practical Insights from Clinical Practice
Dosing is where experience matters most. In perioperative analgesia, published guidance generally describes small intravenous boluses and continuous infusions at sub-anesthetic doses, far below those used for general anesthesia. In my practice as Dr. Austin Harris, I start low, tailor the dose to the patient’s age, renal and hepatic function, and anesthetic plan, and reassess regularly. In most patients, lower is better, because the analgesic benefit is achievable well below the doses that cause psychomimetic effects.
Monitoring is straightforward but non-negotiable. Continuous hemodynamic monitoring is standard in cardiac surgery already. Beyond that, I watch for tachycardia and hypertension, sedation level, and any emergence phenomena such as vivid dreams, agitation, or hallucinations. Pre-procedure counseling helps, because patients who know what to expect are less frightened if they do experience perceptual changes. Some teams add a small benzodiazepine or other agent to temper these effects, though I use that sparingly in older patients given the delirium risk.
Patient selection is where judgment counts. Ketamine’s sympathomimetic effects, helpful in many patients, can be a liability in others. In patients with severe uncontrolled hypertension, significant myocardial ischemia where increased oxygen demand is a concern, or certain tachyarrhythmias, I am cautious or avoid it. In patients who are catecholamine-depleted, ketamine’s direct myocardial depressant effects can become apparent. Pulmonary hypertension requires careful thought as well, since the data on pulmonary vascular effects are nuanced. My advice as Austin Harris MD is that these decisions should always be individualized, made with the surgical and intensivist teams, and revisited as the clinical picture changes.
Integration with enhanced recovery is, to me, where ketamine fits best. Programs for enhanced recovery after cardiac surgery emphasize early extubating, early mobilization, reduced opioid exposure, and coordinated multimodal care. Austin Harris MD sees ketamine as supporting each of those goals. When a patient is comfortable, awake, and breathing well, everything downstream tends to go better: chest physiotherapy, ambulation, nutrition, and ultimately discharge. The drug works best as part of a protocol rather than as an isolated intervention.
Looking Ahead
Several directions deserve attention. Researchers are examining optimal dosing windows and whether starting ketamine before incision, rather than after, offers greater protection against central sensitization. There is interest in its role for patients with chronic opioid use or opioid use disorder, who are among the hardest to manage perioperatively. The anti-inflammatory and neuroprotective questions raised by cardiopulmonary bypass call for well-designed trials with meaningful endpoints, not just surrogate markers. Enantiomer-specific formulations such as Esketamine, and combinations with other non-opioid adjuncts, may also refine the risk-benefit balance.
Equally important is better phenotyping. Not every patient benefits equally, and one of the most valuable things the field can do is identify who gains the most and who is at greatest risk. For me, as Dr. Austin Harris, this is the natural next step: moving from “does ketamine work?” to “for whom, at what dose, and in what context?”
A Measured Conclusion
Ketamine infusion therapy is not a miracle drug, and I would be suspicious of anyone who presents it as one. It carries real risks, requires thoughtful patient selection, and works best within a multimodal, enhanced-recovery framework. But used well, it can offer effective analgesia, support hemodynamics, reduce opioid exposure, and help patients recover more comfortably after some of the most demanding operations in medicine. As the evidence matures, I expect its role in cardio-thoracic anesthesiology to become more precisely defined, and, I hope, more beneficial for patients.
About the author: Austin Harris MD is a cardio-thoracic anesthesiologist committed to individualized, evidence-based perioperative care. This article reflects general educational information and professional perspective; it is not medical advice for any specific patient. Anyone considering or facing cardiac or thoracic surgery should discuss anesthetic and pain-management options with their own care team.




